Sponsor Pipeline

Novartis Pharmaceuticals Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
298
Active Trials
154
Recruiting
86
Phase 3
10
Disease Areas
138
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-12 NCT03975829
Pediatric Long-Term Follow-up and Rollover Study
overall status: "Recruiting" → "Active Not Recruiting"
2026-06-12 NCT03374657
A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis…
Trial completed
2026-06-12 NCT06665256
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
overall status: "Recruiting" → "Active Not Recruiting"
2026-06-12 NCT06665256
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
Enrollment reduced: 123 -> 21 participants
2026-06-12 NCT07421167
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice…
date change Primary completion pushed: 2027-03-03 -> 2029-01-10
2026-06-12 NCT07421167
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice…
date change Completion pushed: 2027-03-31 -> 2030-09-18
2026-06-11 NCT07630961
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in…
Recruitment opened
2026-06-11 NCT07517263
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate…
Trial sites expanded: 559 -> 618 locations
2026-06-11 NCT05939414
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation…
Trial sites expanded: 144 -> 147 locations
2026-06-10 NCT07517250
A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease…
date change Primary completion moved earlier: 2027-03-03 -> 2026-12-03
2026-06-10 NCT07517250
A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease…
date change Completion moved earlier: 2027-03-03 -> 2026-12-03
2026-06-10 NCT07468071
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit…
Recruitment opened
2026-06-09 NCT07039422
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody…
Trial sites expanded: 18 -> 22 locations
2026-06-09 NCT07594587
A Study of Ruxolitinib in Patients With Graft-Versus Host Disease
Recruitment opened
2026-06-09 NCT07594587
A Study of Ruxolitinib in Patients With Graft-Versus Host Disease
date change Primary completion pushed: 2030-03-15 -> 2030-05-15
2026-06-09 NCT07594587
A Study of Ruxolitinib in Patients With Graft-Versus Host Disease
date change Completion pushed: 2030-03-15 -> 2030-05-15
2026-06-09 NCT07326709
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants…
Trial sites expanded: 13 -> 20 locations
2026-06-09 NCT06824103
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With…
date change Primary completion moved earlier: 2029-11-29 -> 2029-05-10
2026-06-09 NCT07422610
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies…
Trial sites expanded: 2 -> 5 locations
2026-06-09 NCT07235046
A Study of DII235 in Adults With Elevated Lipoprotein(a)
date change Primary completion moved earlier: 2027-09-08 -> 2027-04-26
Showing 20 of 138 changes detected in the last 30 days.
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-11 NCT07642557 Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT) Not Yet Recruiting
2026-06-09 NCT07635316 A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor… Not Yet Recruiting
2026-06-05 NCT07630961 Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in… Phase 1 Recruiting
2026-06-04 NCT07625306 Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and… Phase 3 Not Yet Recruiting
2026-06-04 NCT07626281 Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New… Phase 1 Not Yet Recruiting
2026-06-02 NCT07621809 Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus… Phase 3 Not Yet Recruiting
2026-05-27 NCT07610278 A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in… Phase 2 Not Yet Recruiting
2026-05-22 NCT07604324 A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and… Phase 1 Recruiting
2026-05-22 NCT07604571 Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2… Phase 1 Recruiting
2026-05-20 NCT07598422 A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients… Not Yet Recruiting
Active Trials by Phase
Phase 4
22
Phase 3
84
Phase 2/3
2
Phase 2
56
Phase 1/2
27
Phase 1
33
Not specified
74
Active Trials — top 25 of 298
NCT IDTitleConditionStatus
Phase 4
NCT06501443 LATAM LOWERS LDL-C Hypercholesterolaemia Recruiting
NCT07034690 Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in… Atherosclerotic Cardiovascular Disease Recruiting
NCT06733922 ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS Relapsing Remitting Multiple Sclerosis (RRMS) Recruiting
NCT04480853 Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing… Multiple Sclerosis Recruiting
NCT06372925 Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute… Plaque, Atherosclerotic Recruiting
NCT04638647 Secukinumab Open Label Roll-over Extension Protocol Autoimmunity, Inflammation Recruiting
NCT07489573 Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to… Hidradenitis Suppurativa (HS) Recruiting
NCT05803941 Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate… Prostate Cancer Recruiting
NCT04657822 Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior… Sickle Cell Disease Recruiting
NCT06824103 Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With… Graft vs. Host Disease Recruiting
NCT03340506 Dabrafenib and/or Trametinib Rollover Study Melanoma Recruiting
NCT04877522 Asciminib Roll-over Study Chronic Myelogenous Leukemia Recruiting
NCT06444113 Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of… Multiple Sclerosis Active, Not Recruiting
NCT02386800 CINC424A2X01B Rollover Protocol Primary Myelofibrosis Active, Not Recruiting
NCT05090371 A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After… Relapsing-Remitting Multiple Sclerosis Active, Not Recruiting
NCT06941792 Inclisiran Effectiveness in China: a Pragmatic Randomized Trial Coronary Heart Disease Active, Not Recruiting
NCT07448610 ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants… Spinal Muscular Atrophy Not Yet Recruiting
NCT05622708 A Study of Secukinumab to Evaluate Maintenance of Response in Participants With… Non-radiographic Axial Spondyloarthritis Active, Not Recruiting
NCT02584933 Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib… ALK Positive Malignancies Active, Not Recruiting
NCT03975829 Pediatric Long-Term Follow-up and Rollover Study Diffuse Astrocytoma Active, Not Recruiting
NCT05161195 Roll-over Study to Allow Continued Access to Ribociclib Metastatic Breast Cancer Active, Not Recruiting
NCT05252585 A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous… Renal Angiomyolipoma Active, Not Recruiting
Phase 3
NCT05335876 Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in… Spinal Muscular Atrophy (SMA) Recruiting
NCT06597006 Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With… Familial Hypercholesterolemia - Homozygous Recruiting
NCT06711887 Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study… Lupus Nephritis Recruiting
View all 298 active Novartis Pharmaceuticals trials with filters →
Disease Areas
Get alerts when Novartis Pharmaceuticals's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free